MX2007006081A - Tetrahidroisoquinolinas 4-fenil-sustituidas y uso de las mismas para bloquear la recaptacion de norepinefrina, dopamina y serotonina. - Google Patents

Tetrahidroisoquinolinas 4-fenil-sustituidas y uso de las mismas para bloquear la recaptacion de norepinefrina, dopamina y serotonina.

Info

Publication number
MX2007006081A
MX2007006081A MX2007006081A MX2007006081A MX2007006081A MX 2007006081 A MX2007006081 A MX 2007006081A MX 2007006081 A MX2007006081 A MX 2007006081A MX 2007006081 A MX2007006081 A MX 2007006081A MX 2007006081 A MX2007006081 A MX 2007006081A
Authority
MX
Mexico
Prior art keywords
norepinephrine
serotonin
dopamine
phenyl substituted
substituted tetrahydroisoquinolines
Prior art date
Application number
MX2007006081A
Other languages
English (en)
Inventor
Bruce F Molino
Marlene Cohen
Barry Berkowitz
Original Assignee
Amr Technology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amr Technology Inc filed Critical Amr Technology Inc
Publication of MX2007006081A publication Critical patent/MX2007006081A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)

Abstract

La presente invencion se refiere a un metodo para tratar trastornos al administrar un compuesto de las formulas IA-IF. Estos compuestos son tetrahidroisoquinolinas de la siguiente estructura: en donde R1-R8 para los compuestos de cada una de las formulas IA, IB, IC, ID, IE y IF son como se describen en la presente.
MX2007006081A 2004-11-22 2005-11-21 Tetrahidroisoquinolinas 4-fenil-sustituidas y uso de las mismas para bloquear la recaptacion de norepinefrina, dopamina y serotonina. MX2007006081A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/994,688 US20060111393A1 (en) 2004-11-22 2004-11-22 4-Phenyl substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine and serotonin
PCT/US2005/042110 WO2006057950A2 (en) 2004-11-22 2005-11-21 4-phenyl substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine and serotonin

Publications (1)

Publication Number Publication Date
MX2007006081A true MX2007006081A (es) 2007-07-11

Family

ID=36461730

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2007006081A MX2007006081A (es) 2004-11-22 2005-11-21 Tetrahidroisoquinolinas 4-fenil-sustituidas y uso de las mismas para bloquear la recaptacion de norepinefrina, dopamina y serotonina.

Country Status (13)

Country Link
US (2) US20060111393A1 (es)
EP (1) EP1827435A4 (es)
JP (1) JP2008520720A (es)
KR (1) KR20070090211A (es)
CN (1) CN101094672A (es)
AU (1) AU2005309765A1 (es)
BR (1) BRPI0518043A (es)
CA (1) CA2588773A1 (es)
IL (1) IL183325A0 (es)
MX (1) MX2007006081A (es)
NO (1) NO20073208L (es)
RU (1) RU2007123393A (es)
WO (1) WO2006057950A2 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4907818B2 (ja) * 1999-11-03 2012-04-04 エーエムアール テクノロジー インコーポレイテッド アリールおよびヘテロアリール置換テトラヒドロイソキノリン、ならびにノルエピネフリン、ドーパミンおよびセロトニンの再取り込みを阻止するためのそれらの使用
CN100430401C (zh) * 2000-07-11 2008-11-05 Amr科技公司 新的4-苯基取代的四氢异喹啉类化合物及其治疗用途
WO2006020049A2 (en) 2004-07-15 2006-02-23 Amr Technology, Inc. Aryl-and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
US20060111393A1 (en) * 2004-11-22 2006-05-25 Molino Bruce F 4-Phenyl substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine and serotonin
US20060111385A1 (en) * 2004-11-22 2006-05-25 Molino Bruce F Novel 4-phenyl substituted tetrahydroisoquinolines and therapeutic use thereof
US20060111394A1 (en) * 2004-11-22 2006-05-25 Molino Bruce F Aryl-and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine and serotonin
KR20060059728A (ko) * 2004-11-29 2006-06-02 삼성에스디아이 주식회사 액정 표시 장치 및 그 제조 방법
KR101589551B1 (ko) * 2005-07-15 2016-02-02 알바니 몰레큘라 리써치, 인크. 아릴- 및 헤테로아릴-치환된 테트라히드로벤자제핀, 및 노르에피네프린, 도파민 및 세로토닌의 재흡수를 차단하기 위한 용도
US9156812B2 (en) 2008-06-04 2015-10-13 Bristol-Myers Squibb Company Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
AR071997A1 (es) * 2008-06-04 2010-07-28 Bristol Myers Squibb Co Forma cristalina de 6-((4s)-2-metil-4-(2-naftil)-1,2,3,4-tetrahidroisoquinolin-7-il)piridazin-3-amina
CA2760837C (en) * 2009-05-12 2018-04-03 Albany Molecular Research, Inc. 7-([1,2,4]triazolo[1,5-.alpha.]pyridin-6-yl)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydroisoquinoline and use thereof
EP2429293B1 (en) * 2009-05-12 2014-10-29 Bristol-Myers Squibb Company CRYSTALLINE FORMS OF (S)-7-([1,2,4]TRIAZOLO[1,5-a]PYRIDIN-6-YL)-4-(3,4-DICHLOROHPHENYL)-1,2,3,4-TETRAHYDROISOQUINOLINE AND USE THEREOF
KR20120034644A (ko) * 2009-05-12 2012-04-12 알바니 몰레큘라 리써치, 인크. 아릴, 헤테로아릴, 및 헤테로사이클 치환된 테트라하이드로이소퀴놀린 및 이의 용도
EP2420237A1 (en) * 2010-08-11 2012-02-22 Ville Takio Fluorinated derivatives of endogenous isoquinolines for use in the treatment of diseases mediated through endogenous isoquinoline pathways
EP2606049A4 (en) 2010-08-17 2014-01-08 Albany Molecular Res Inc 2,5-METHANO- AND 2,5-ETHANO-TETRAHYDROBENZAZEPINE DERIVATIVES AND USES THEREOF FOR BLOCKING NOREPINEPHRINE, DOPAMINE, AND SEROTONIN REUPTAKE

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3947456A (en) * 1970-01-06 1976-03-30 Hoffman-La Roche Inc. Substituted 4-phenyl isoquinolines
US3666763A (en) * 1970-01-06 1972-05-30 Hoffmann La Roche 4-phenyl isoquinolines and process for preparing same
GB1504424A (en) * 1975-08-09 1978-03-22 Beecham Group Ltd Isoquinoline-derived aminoethers
US4340600A (en) * 1980-05-22 1982-07-20 Smithkline Corporation Renal dilating methods and compositions using 4-(3,4-dihydroxyphenyl)-1,2,3,4-tetrahydroisoquinolines
DE3333994A1 (de) * 1983-09-21 1985-04-04 Troponwerke GmbH & Co KG, 5000 Köln Neue pyridoindolderivate, verfahren zu ihrer herstellung und ihre verwendung
US4843071A (en) * 1986-12-05 1989-06-27 Serotonin Industries Of Charleston Method and composition for treating obesity, drug abuse, and narcolepsy
ZA885824B (en) * 1987-08-14 1989-04-26 Merrell Dow Pharma Novel antidepressants
US4902710A (en) * 1988-12-14 1990-02-20 Eli Lilly And Company Serotonin and norepinephrine uptake inhibitors
US5114976A (en) * 1989-01-06 1992-05-19 Norden Michael J Method for treating certain psychiatric disorders and certain psychiatric symptoms
US5481667A (en) * 1992-02-13 1996-01-02 Microsoft Corporation Method and system for instructing a user of a computer system how to perform application program tasks
DK154192D0 (da) * 1992-12-23 1992-12-23 Neurosearch As Heterocycliske forbindelser
US5607939A (en) * 1994-04-28 1997-03-04 Takeda Chemical Industries, Ltd. Condensed heterocyclic compounds, their production and use
CA2134038C (en) * 1994-06-16 1997-06-03 David Taiwai Wong Potentiation of drug response
US6121261A (en) * 1997-11-19 2000-09-19 Merck & Co., Inc. Method for treating attention deficit disorder
US6239800B1 (en) * 1997-12-15 2001-05-29 International Business Machines Corporation Method and apparatus for leading a user through a software installation procedure via interaction with displayed graphs
JP4907818B2 (ja) * 1999-11-03 2012-04-04 エーエムアール テクノロジー インコーポレイテッド アリールおよびヘテロアリール置換テトラヒドロイソキノリン、ならびにノルエピネフリン、ドーパミンおよびセロトニンの再取り込みを阻止するためのそれらの使用
JP4907817B2 (ja) * 1999-11-03 2012-04-04 エーエムアール テクノロジー インコーポレイテッド ノルエピネフリン、ドーパミンおよびセロトニンの再取り込みを遮断するための、４−フェニル置換テトラヒドロイソキノリン類およびその利用
EP1113007A1 (en) * 1999-12-24 2001-07-04 Pfizer Inc. Tetrahydroisoquinoline compounds as estrogen agonists/antagonists
CN100430401C (zh) * 2000-07-11 2008-11-05 Amr科技公司 新的4-苯基取代的四氢异喹啉类化合物及其治疗用途
JP4510457B2 (ja) * 2001-12-05 2010-07-21 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 置換４−フェニルテトラヒドロイソキノリン類、その製造方法、その医薬としての用途、およびそれらを含む医薬
US6911453B2 (en) * 2001-12-05 2005-06-28 Aventis Pharma Deutschland Gmbh Substituted 4-phenyltetrahydroisoquinolinium, process for their preparation, their use as a medicament, and medicament containing them
WO2006020049A2 (en) * 2004-07-15 2006-02-23 Amr Technology, Inc. Aryl-and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
US20060111394A1 (en) * 2004-11-22 2006-05-25 Molino Bruce F Aryl-and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine and serotonin
US20060111393A1 (en) * 2004-11-22 2006-05-25 Molino Bruce F 4-Phenyl substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine and serotonin
US20060111385A1 (en) * 2004-11-22 2006-05-25 Molino Bruce F Novel 4-phenyl substituted tetrahydroisoquinolines and therapeutic use thereof

Also Published As

Publication number Publication date
WO2006057950A3 (en) 2006-10-26
BRPI0518043A (pt) 2008-10-28
KR20070090211A (ko) 2007-09-05
EP1827435A2 (en) 2007-09-05
CN101094672A (zh) 2007-12-26
IL183325A0 (en) 2007-09-20
AU2005309765A1 (en) 2006-06-01
RU2007123393A (ru) 2008-12-27
WO2006057950A2 (en) 2006-06-01
EP1827435A4 (en) 2011-08-31
NO20073208L (no) 2007-08-22
CA2588773A1 (en) 2006-06-01
US20060111393A1 (en) 2006-05-25
US20060111396A1 (en) 2006-05-25
JP2008520720A (ja) 2008-06-19

Similar Documents

Publication Publication Date Title
MX2007006081A (es) Tetrahidroisoquinolinas 4-fenil-sustituidas y uso de las mismas para bloquear la recaptacion de norepinefrina, dopamina y serotonina.
GEP20125566B (en) Aryl-and heteroaryl-substituded tetrahydro-benzazepines and use thereof to block reuptake of norepinephrine, dopamine and serotonin
MX2007006082A (es) Tetrahidroisoquinolinas aril- y heteroaril-sustituidas, y uso de las mismas para bloquear la recaptacion de norepinefrina, dopamina y serotonina.
WO2009089537A3 (en) Anti-cancer compounds
MX2020010151A (es) Analogos de piridazina 1,4-disustituida y metodos para el tratamiento de condiciones relacionadas con la deficiencia de smn.
SI2044043T2 (sl) 1-2(-2,4-dimetilfenilsulfanil)-fenil)piperazin hidrobromid kot spojina s kombinirano aktivnostjo ponovnega privzema serotonina, 5-ht3 in 5-ht1a za zdravljenje kognitivne motnje
HK1112238A1 (en) Substituted benzo(d)isoxazol-3-yl amine compounds as analgesics
TW201000473A (en) Benzene or thiophene derivative and use thereof as VAP-1 inhibitor
EA201070477A1 (ru) Транс-кломифен для лечения метаболического синдрома
EA201290397A1 (ru) 1,3,4-оксадиазол-2-карбоксамидное соединение
TN2012000248A1 (en) Novel spiropiperidine compounds
TW200942524A (en) Novel aminomethyl benzene derivatives
MX2009011923A (es) Tetrahidrobenzo-1,4-diazepinas aril- y heteroaril-sustituidas y uso de las mismas para bloquear reabsorcion de norepinefrina, dopamina y serotonina.
MY151211A (en) 4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compounds
SE0401465D0 (sv) New substituted piperdines as modulators of dopamine neurotransmission
WO2013036015A3 (ko) 아제티딘 유도체 및 이를 함유하는 항우울제 조성물
TW200631952A (en) Benzdioxan piperazine derivatives with a combination of affinity for dopamine-D2 receptors and serotonin reuptake sites
WO2006133339A3 (en) Monoamine re-uptake inhibitors and methods relating thereto
TW200633987A (en) Phenylpiperazines with a combination of affinity for dopamine-D2 receptors and serotonin reuptake sites
MX2011012596A (es) Metodos para incrementar os efectos de un inhibidor selectivo de la recaptacion de serotonina en los mamiferos.
WO2009126844A3 (en) Deuterium labelled derivatives of 3-(2-hydroxy-5-methyphenyl)-n,n-diisopropyl-3-phenylpropylamine and methods of use thereof
EA201070334A1 (ru) Пиперидиниламинотиено[2,3-d]пиримидиновые соединения для лечения фиброза
UA90656C2 (ru) Габоксадол для лечения депрессии
TW200616637A (en) Novel quinoxalinone norepinephrine reuptake inhibitors for the treatment of central nervous system disorders
EA200802000A1 (ru) Фармацевтически приемлемые соли и полиморфные формы

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: ALBANY MOLECULAR RESEARCH, INC.

FA Abandonment or withdrawal